Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
Targeting ROR1 and a two-drug approach to cure CLL
Panel discussion on mantle cell lymphoma
Constantine Tam et al.
Era of personalized therapy in CLL
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL